HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Dr. Reddy's Laboratories launches NIVORZ in India
Sep-16-2026

Dr. Reddy's Laboratories has launched ‘NIVORZ’ (Nivolumab Biosimilar) in India. NIVORZ is a biosimilar to Opdivo (nivolumab). Developed and manufactured entirely in-house at the company’s biologics facility in Bachupally, Hyderabad, it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialization. 

The launch of NIVORZ further strengthens the company's oncology portfolio and expands its presence in immuno-oncology. The Immuno-Oncology market in India is estimated at around Rs 3,900 crore in 2025 and is predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab. Access to immuno-oncology therapies remains a challenge for many patients due to the cost and duration of treatment. Through NIVORZ, the company aims to broaden access to high-quality nivolumab therapy with an affordable biosimilar option for eligible patients.

NIVORZ (Nivolumab) is one of the immunotherapy agents with the broadest range of approved indications in oncology in India, including Metastatic Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Melanoma, Classical Hodgkin Lymphoma (cHL), Urothelial Carcinoma (UC), Colorectal Cancer (CRC), Esophageal squamous cell carcinoma (ESCC), Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma (GC, GEJC or EAC), Adjuvant treatment of Resected Esophageal or Gastroesophageal Junction Cancer (EC or GEJC), Malignant Pleural Mesothelioma (MPM) and Hepatocellular Carcinoma (HCC). Together, these approved indications span early-stage, locally advanced, recurrent, and metastatic disease settings across both solid and hematological malignancies.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

  RELATED NEWS >>